Cheryl cohen working with one goal. Commercialize Aldoxorubicin.
FDA APPROVED MULTIPLE ORPHAN drug status designations for Aldoxorubicin with exclusivity for each designation for7 years Plus the European medicine agency approved orphan drug status designation for Aldoxorubicin with exclusivity for 10 years Also the FDA has approved special protocol assessment for Aldoxorubicin with extended dosing for patients since January 2014. Hold onto your shares
my guess is one of the six figure guys dropped the ball... 5-21-15 Dr. Levitt says cytrx will present GBM trial data in 2015 at a neuro oncology conference... but the abstract had to be submitted by 6-15-2015 with a 9-1-2015 late abstract submittal... where's the accountability and transparency to shareholders !!!!
cytrx will not be at SNO conference because they are still recruiting and treating GBM patients. cofirmed by matt from trout
care to co9mment on how 18 guys sitting in LA will get this done. answer is that CEO has every intention of selling out.
Simple stufffffffff FDA shortage doxorubicin. Aldoxorubicin will replace doxorubicin. CYTR has worldwide rights
Looks like until any good news comes out CYTR will just track along with IBB Bio Tech ETF... very frustrating but probably a good time to add more before we get some news... whenever that may be. But like someone said a while back on this board, one day we may just wake up and see this stock up a few bucks with some good news. That is way I'm willing to wait another year or so if needed... though I'm a very patient person.
The 1st update of just 7 patients was very encouraging even though only 3 cycles were administered. Even the recently started single agent trial for sclc will be interesting
FDA shortage list Doxorubicin. FDA APPROVED MULTIPLE ORPHAN drug status designations for Aldoxorubicin with exclusivity for each designation for 7 years. The European medicine agency approved orphan drug status for Aldoxorubicin with exclusivity for 10 years. CYTR has worldwide rights to Aldoxorubicin
JAMA acknowledging Aldox orubicin.FDA hand holding Aldoxorubicin through the APPROVAL process
Hi Shadow. I don't believe anything was ever posted on timing for those. You would think data would be available early 2016 and that is part of my 2016 good news thesis. :)
The best has yet to come, when both combo Ph1 studies start working their respective synergistic 'magic'. I am particularly interested in the solid tumor studies. That approach will be really big, imho. I am glad I added more into cytr during the dip.